| Previous Close | 77.38 |
| Open | 77.53 |
| Bid | 76.48 x 500 |
| Ask | 80.25 x 200 |
| Day's Range | 77.53 - 78.65 |
| 52 Week Range | 64.18 - 86.72 |
| Volume | 2,130,391 |
| Avg. Volume | 3,604,756 |
| Market Cap | 81.95B |
| Beta | 0.15 |
| PE Ratio (TTM) | 37.84 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.70%) |
| Ex-Dividend Date | 2017-08-11 |
| 1y Target Est | N/A |
- Market Realist•3 hours ago
Understanding Incyte’s 2Q17 Revenue Stream
Incyte's 2Q17 revenue growth was driven by the increased demand for Jakafi.
Markit•9 hours agoSee what the IHS Markit Score report has to say about Eli Lilly And Co.
Eli Lilly And Co NYSE:LLY
- Motley Fool•10 hours ago
3 Most Promising Cancer Drugs in Late-Stage Development
Eli Lilly, Incyte, and Johnson & Johnson could have the most exciting late-stage oncology candidates.
